Risk Stratification for the Occurrence of Ventricular Fibrillation in Patients with Early Repolarization Syndrome
Several signs of malignant early repolarizations (ERs) have been proposed in patients with ER syndrome (ERS). However, recent reports have challenged the efficacy of these signs in predicting future ventricular fibrillation (VF) in patients with ERS. (Source: Heart Rhythm)
Source: Heart Rhythm - May 4, 2024 Category: Cardiology Authors: Hiroshi Morita, Saori Asada, Akira Ueoka, Tomofumi Mizuno, Takuro Masuda, Masakazu Miyamoto, Satoshi Kawada, Koji Nakagawa, Nobuhiro Nishii, Shinsuke Yuasa Source Type: research
Catheter ablation for atrial fibrillation in heart failure with reduced ejection fraction patients: A meta-analysis
The optimal treatment for atrial fibrillation (AF) in patients with heart failure with reduced ejection fraction (HFrEF) remains unsettled. (Source: Heart Rhythm)
Source: Heart Rhythm - May 3, 2024 Category: Cardiology Authors: Eric Pasqualotto, Caique M.P. Ternes, Matheus Pedrotti Chavez, Carisi A. Polanczyk, Rafael Oliva Morgado Ferreira, Thiago Nienk ötter, Gustavo de Oliveira Almeida, Edmundo Bertoli, Mariana R.C. Clemente, Andre d'Avila, Luis E. Rohde Source Type: research
Atrial Fibrillation and Heart Failure: to build a CASTLE you need a solid foundation
The authors claim that their score identifies heart failure (HF) patients who benefit the most from atrial fibrillation (AF) ablation. However, the crude hazard ratio (HR) for the primary endpoint was 0.32 in favour of ablation in the “high-risk group” and 0.41 in the “low-risk group”. Thus, AF ablation appears to perform equally well in both groups, but the higher number of events makes this different statistically significant only in the high-risk group. More than identifying patients who benefit from the ablation, the score seems to identify patients who will have worse outcomes, irrespective of the treatment st...
Source: Heart Rhythm - May 3, 2024 Category: Cardiology Authors: Marco Bergonti, Giulio Conte Source Type: research
Author's reply to Atrial Fibrillation and Heart Failure: to build a CASTLE you need a solid foundation
To fully understand the predictive value of the CASTLE-HTx risk-score in relation to the benefits of catheter ablation in patients with end-stage heart failure (HF) and atrial fibrillation (AF), it is essential to distinguish between absolute and relative risk reduction. The observed hazard ratios (HR) favoring ablation of 0.32 and 0.41 for high-risk and low-risk patients, respectively, did not differ substantially on a relative scale. On an absolute scale, the incidence rate difference with ablation observed in high-risk patients (24.69/100 patient years) was significantly greater than that observed in low-risk patients (...
Source: Heart Rhythm - May 3, 2024 Category: Cardiology Authors: Maximilian Moersdorf, Jan G.P. Tijssen, Philipp Sommer, Christian Sohns Source Type: research
Fine-tuning early rhythm control strategies for atrial fibrillation – Timing matters to stay in sync
Rhythm control with either medications or catheter ablation is an established strategy for symptomatic patients with atrial fibrillation (AF), by reducing arrhythmic burden and improving patient quality of life, as well as reducing the risk of heart failure hospitalization and mortality in select populations with concomitant AF and heart failure. The 2023 ACC/AHA/ACCP/HRS guideline on AF management also underscores the role for early rhythm control in patients with recent AF diagnosis ( (Source: Heart Rhythm)
Source: Heart Rhythm - May 3, 2024 Category: Cardiology Authors: Bert Vandenberk, Derek S. Chew Source Type: research
Lb-469807-01 impact of vigorous exercise in the long qt syndrome by genotype, age, and sex: data from the lifestyle and exercise in long qt syndrome registry (live-lqts)
In the multinational, NIH-funded, LIVE-LQTS, ventricular arrhythmia (VA) event rate was low in participants engaged in vigorous exercise and in the less active, in a largely appropriately-treated cohort. Genotype, age, and sex impact risk in LQTS, and triggers of VA differ. This analysis assesses if habitual vigorous exercise impacts VA risk and triggers differently, based on these features. (Source: Heart Rhythm)
Source: Heart Rhythm - May 2, 2024 Category: Cardiology Authors: Rachel Lampert, Sharlene Day, Barbara Ainsworth, Mathew Burg, Bradley Marino, Lisa R. Salberg, Maria Teresa Tome Esteban, Dominic J. Abrams, Peter F. Aziz, Cheryl Barth, Elijah Behr, Cheyenne Bell, Charles I. Berul, Johan M. Bos, David J. Bradley, David S Source Type: research
Lb-469807-02 left bundle branch area pacing using a stylet driven, retractable helix lead: results from a prospective, multicenter trial (the bio-conduct study)
The objective is to prospectively evaluate performance and safety of these leads. (Source: Heart Rhythm)
Source: Heart Rhythm - May 2, 2024 Category: Cardiology Authors: Christopher F. Liu, Karthik Prasad, Antonio Moretta, Pugazhendhi Vijayaraman, Francesco Zanon, Camden Harrell, Crystal Miller, Marye J. Gleva, Jan De Pooter, Larry A. Chinitz Source Type: research
Lb-469807-03 early cardiac resynchronization therapy for patients with moderately reduced ejection fraction and left bundle branch block
CRT improves left ventricular ejection fraction (LVEF) and survival for patients (pts) with advanced heart failure (HF). It is not known if CRT would improve or halt the progression of HF in patients with moderately reduced LVEF (HFmrEF) and LBBB. (Source: Heart Rhythm)
Source: Heart Rhythm - May 2, 2024 Category: Cardiology Authors: Yong-Mei Cha, Hon-Chi Lee, Siva K. Mulpuru, Abhishek J. Deshmukh, Samuel J. Asirvatham, Paul A. Friedman, David Bradley, Songnan Wen, Brian Liddell, Caroline G. Curran, Chuanwei Li, Kent R. Bailey, Horng Chen Source Type: research
Lb-469807-04 efficacy and safety of apixaban versus aspirin according to cha2ds2-vasc score in patients with subclinical atrial fibrillation in artesia
ARTESiA showed that apixaban, compared to aspirin, significantly reduced stroke or systemic embolism (SE) but increased major bleeding in patients with subclinical atrial fibrillation (SCAF). To better inform benefit-to-risk decision-making for the use of apixaban, we evaluated the benefits and hazards of apixaban according to baseline CHA2DS2-VASc score. (Source: Heart Rhythm)
Source: Heart Rhythm - May 2, 2024 Category: Cardiology Authors: Jeffrey S. Healey, Christopher Granger, William F. McIntyre, Marco Alings, Daniel Wojdyla, Chinthanie Ramasundarahettige, Lena Rivard, Dan Atar, David H. Birnie, Giuseppe Boriani, Guy Amit, Peter Leong-Sit, Claus H. Rinne, Gabor Duray, Michael R. Gold, St Source Type: research
Lb-469807-05 outcomes with and without oral anticoagulation in patients with prior stroke and device-detected atrial fibrillation: the noah-afnet 6 trial
Patients with a prior stroke are at high risk of recurrent strokes. In patients with ECG-documented atrial fibrillation (AF), anticoagulation reduces subsequent strokes. Detection of short and rare episodes of atrial fibrillation using implanted devices (device-detected AF, DDAF) is common in patients with a prior stroke and these patients are often treated with an anticoagulant when DDAF is detected. Data on the effectiveness and safety of oral anticoagulation in patients a prior stroke and DDAF but no ECG-documented AF are lacking. (Source: Heart Rhythm)
Source: Heart Rhythm - May 2, 2024 Category: Cardiology Authors: Hans Diener, Gregory Lip, Julius Nikorowitsch, Nina Becher, Carina Blomstr öm-Lundqvist, A. John Camm, Gregory Chlouverakis, Andreas Goette, Ulrich Schotten, Emmanuel Simantirakis, Tobias Toennis, Panos Vardas, Antonia Zapf, Susanne Sehner, Renate B. Sch Source Type: research
Lb-469809-01 mediterranean diet enriched with extra-virgin olive oil reduced risk of tachyarrhythmia recurrence after atrial fibrillation ablation: the predimar trial
AF ablation has limited success. The PREDIMED trial showed that a Mediterranean diet(MeDiet) enriched with extra-virgin olive oil (EVOO) reduces incidental AF. The PREDIMAR trial assessed the effect of this dietary pattern on arrhythmia recurrence after ablation. (Source: Heart Rhythm)
Source: Heart Rhythm - May 2, 2024 Category: Cardiology Authors: Maria T. Barrio-Lopez, Miguel Angel Martinez Gonzalez, Jesus Almendral, Pablo Ramos Ardanaz, Luis Tercedor, Jose L. Iba ñez Criado, Leticia Goni, Victor de la O, Ignacio Garcia-Bolao, Rosa Macias, Alicia Ibañez Criado, Miguel Ruiz-Canela Source Type: research
Lb-469809-02 impact of pulsed field vs thermal ablation on one-year atrial arrhythmia burden – sub-analysis of the advent trial
ADVENT revealed no significant difference in 1-year freedom from atrial arrhythmias (AA) between thermal and pulsed field ablation (PFA). However, recent studies indicate that the post-ablation AA burden is a better predictor of clinical outcomes than the dichotomous endpoint of 30-sec AA recurrence. Herein, we studied the impact of post-ablation AA burden on outcomes, and the effect of ablation modality on AA burden in ADVENT. (Source: Heart Rhythm)
Source: Heart Rhythm - May 2, 2024 Category: Cardiology Authors: Vivek Y. Reddy, Moussa Mansour, Hugh Calkins, Jonathan Waks, Larry A. Chinitz, Christopher E. Woods, Sanjaya K. Gupta, Jamie Kim, Zayd A. Eldadah, Robert A. Pickett, Jeffrey R. Winterfield, Wilber W. Su, Christopher Schneider, Elizabeth Richards, Elizabet Source Type: research
Lb-469809-03 short- and long-term clinical outcomes of radiofrequency catheter ablation in paroxysmal atrial fibrillation: results from the prospective multicenter real-af registry
The impact of contemporary techniques and technologies to optimize ablation delivery, reduce fluoroscopy use, and improve clinical outcomes using radiofrequency catheter ablation (RF-CA) for paroxysmal atrial fibrillation (PAF) has not been assessed in systematic, large, prospective, multicenter registries. We aimed to assess the contemporary real-world practice approach, procedural and long-term clinical outcomes of RF-CA for PAF through a large prospective multicenter registry. (Source: Heart Rhythm)
Source: Heart Rhythm - May 2, 2024 Category: Cardiology Authors: Paul C. Zei, Jose Osorio, Andr és F. Miranda-Arboleda, Joshua R. Silverstein, Saumil R. Oza, Anthony R. Magnano, Jorge Romero, Carlos D. Matos, Carolina Hoyos, Fernando Moreno, Daniela Hincapie Tabares, Anil Rajendra, Gustavo X. Morales, Alexandru I. Cos Source Type: research
Lb-469809-04 safety and effectiveness of pulsed field ablation for atrial fibrillation in patients with heart failure: a manifest-pf registry sub-analysis
Atrial fibrillation (AF) and heart failure (HF) coexist, increasing morbidity and mortality. RCTs have shown improved clinical outcomes following AF ablation in HF patients with reduced EF. Pulsed-field ablation (PFA) preferentially targets myocardial tissue but its outcomes in HF is unknown. (Source: Heart Rhythm)
Source: Heart Rhythm - May 2, 2024 Category: Cardiology Authors: Mohit K. Turagam, Petr Neuzil, Boris Schmidt, Tobias Reichlin, Kars Neven, Andreas Metzner, Jim Hansen, Yuri Blaauw, Philippe Maury, Thomas Arentz, Philipp Sommer, Ante Anic, Frederic Anselme, Serge Boveda, Tom Deneke, Stephan Willems, Pepijn van der Voor Source Type: research
Lb-469805-01 tailored cardiac ablation procedure for persistent atrial fibrillation guided by artificial intelligence: the tailored-af randomized clinical trial
While pulmonary vein isolation (PVI) remains the cornerstone ablation procedure for paroxysmal atrial fibrillation (AF), the optimal procedure for persistent and long-standing persistent AF patients remains elusive. (Source: Heart Rhythm)
Source: Heart Rhythm - May 2, 2024 Category: Cardiology Authors: Isabel Deisenhofer, Jean-Paul Albenque, Sonia Busch, Edouard Gitenay, Stavros Mountantonakis, Antoine Roux, Jerome Horvilleur, Bab é Bakouboula, Saumil R. Oza, Selim Abbey, Guillaume Théodore, Antoine Lepillier, Yves Guyomar, Francis Bessiere, Paola Mil Source Type: research
